Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.
Giuseppe Buono(Federico II University Hospital), Grazia Arpino(University of Naples Federico II), Massimo Di Maïo(University of Siena), Marta Bonotto(University of Udine), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), N.M. La Verde(ASST Fatebenefratelli Sacco), Katia Cannita(Ospedale San Giuseppe), Filippo Montemurro(Roche (Switzerland)), Alberto Zambelli, Michele Bartoletti(Humanitas University), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Sara Parola, Alessandra Fabi(Agostino Gemelli University Polyclinic), Benedetta Conte(Ospedale Policlinico San Martino), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lucia Del Mastro(Ospedale Policlinico San Martino), Raffaele Ardito(Centro di Riferimento Oncologico della Basilicata), Sabino De Placido, Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 6
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830